Published in J Clin Psychiatry on May 01, 2006
The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int (2013) 2.73
Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab (2015) 1.63
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat (2007) 0.87
The adverse event profile of pregabalin across different disorders: a meta-analysis. Eur J Clin Pharmacol (2012) 0.86
Similarities between interstitial cystitis/bladder pain syndrome and vulvodynia: implications for patient management. Transl Androl Urol (2015) 0.85
Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim Care Companion CNS Disord (2011) 0.82
The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci (2008) 0.82
A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat (2012) 0.81
Pregabalin effects on neural response to emotional faces. Front Hum Neurosci (2012) 0.81
The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic. Neuropsychiatr Dis Treat (2007) 0.81
Pregabalin in the management of partial epilepsy. Neuropsychiatr Dis Treat (2009) 0.80
Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat (2013) 0.77
The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat (2016) 0.77
Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers. Psychopharmacology (Berl) (2011) 0.76
Does pregabalin have neuropsychotropic effects?: a short perspective. Psychiatry Investig (2009) 0.76
Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder. Evid Based Ment Health (2007) 0.76
Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors. Ann Gen Psychiatry (2015) 0.75
Pharmacological treatment of diabetic peripheral neuropathy. P T (2015) 0.75
Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice. Drug Des Devel Ther (2015) 0.75
Generalised anxiety disorder. BMJ Clin Evid (2011) 0.75
A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal. Cost Eff Resour Alloc (2013) 0.75
Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry (2014) 0.75
Efficacy and safety of premedication with single dose of oral pregabalin in children with dental anxiety: A randomized double-blind placebo-controlled crossover clinical trial. Dent Res J (Isfahan) (2016) 0.75
The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int (2013) 2.73
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry (2008) 2.64
Reduced resting-state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder. Neuroimage (2011) 2.05
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry (2009) 1.87
Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology (2002) 1.82
Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression. Ann Med (2007) 1.77
A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol (2003) 1.74
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry (2003) 1.66
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol (2007) 1.64
Evaluation of the Two-Way Communication Checklist as a clinical intervention. Results of a multinational, randomised controlled trial. Br J Psychiatry (2004) 1.61
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry (2010) 1.61
Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry (2007) 1.60
Anger attacks in depression--evidence for a male depressive syndrome. Psychother Psychosom (2005) 1.55
The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. Eur J Nucl Med Mol Imaging (2008) 1.55
International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry (2004) 1.50
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.49
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract (2012) 1.49
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry (2013) 1.48
Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry (2006) 1.46
A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry (2004) 1.44
The serotonin-1A receptor in anxiety disorders. Biol Psychiatry (2009) 1.40
Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry (2002) 1.24
Genome scan for susceptibility loci for schizophrenia and bipolar disorder. Biol Psychiatry (2002) 1.23
Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf (2013) 1.23
Differential modulation of the default mode network via serotonin-1A receptors. Proc Natl Acad Sci U S A (2012) 1.22
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry (2002) 1.19
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry (2005) 1.19
Fully exploratory network independent component analysis of the 1000 functional connectomes database. Front Hum Neurosci (2012) 1.18
Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol (2003) 1.17
Regional sex differences in grey matter volume are associated with sex hormones in the young adult human brain. Neuroimage (2009) 1.08
Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol (2007) 1.07
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry (2011) 1.06
Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol (2005) 1.06
Bright-light therapy in the treatment of mood disorders. Neuropsychobiology (2011) 1.05
Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage (2009) 1.04
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry (2002) 1.04
Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol (2007) 1.04
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry (2011) 1.03
Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci (2003) 1.03
Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci (2012) 1.02
Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials. Psychother Psychosom (2015) 1.01
A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol (2007) 0.99
Meta-analysis: fact or fiction? How to interpret meta-analyses. World J Biol Psychiatry (2011) 0.99
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry (2004) 0.99
Actigraphy in patients with seasonal affective disorder and healthy control subjects treated with light therapy. Biol Psychiatry (2005) 0.98
Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology (2007) 0.98
Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol (2011) 0.97
Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs (2012) 0.96
Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol (2011) 0.96
Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling. Neuroimage (2012) 0.95
Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) (2002) 0.94
A highly parallelized framework for computationally intensive MR data analysis. MAGMA (2011) 0.94
Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol (2012) 0.94
Recurrent brief depression revisited. Int Rev Psychiatry (2005) 0.93
Enhanced serotonin transporter function during depression in seasonal affective disorder. Neuropsychopharmacology (2007) 0.93
Guided self-help versus cognitive-behavioral group therapy in the treatment of bulimia nervosa. Int J Eat Disord (2004) 0.93
Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. J Neurosci (2010) 0.93
Normative database of the serotonergic system in healthy subjects using multi-tracer PET. Neuroimage (2012) 0.92
Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects. Hum Brain Mapp (2009) 0.92
RESCALE: Voxel-specific task-fMRI scaling using resting state fluctuation amplitude. Neuroimage (2012) 0.91
The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol (2009) 0.91
Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother (2010) 0.91
Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. Int J Neuropsychopharmacol (2010) 0.91
Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. Neuroimage (2008) 0.90
White matter hyperintensities and chronicity of depression. J Psychiatr Res (2005) 0.90
Imaging treatment effects in depression. Rev Neurosci (2012) 0.90
A comparison of the Major Depression Inventory (MDI) and the Beck Depression Inventory (BDI) in severely depressed patients. Int J Psychiatry Clin Pract (2010) 0.90
Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl) (2006) 0.90
Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. Neuroimage (2012) 0.90
Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl) (2007) 0.89
Current issues in bipolar disorder: a critical review. Eur Neuropsychopharmacol (2007) 0.89
Brightening depression. Science (2004) 0.89
Efficacy of escitalopram compared to citalopram: a meta-analysis. Int J Neuropsychopharmacol (2010) 0.89
Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol (2011) 0.88
Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. Eur Arch Psychiatry Clin Neurosci (2011) 0.88
Neurotransmitters and electroconvulsive therapy. J ECT (2014) 0.87
Role of family history and 5-HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder. Eur Neuropsychopharmacol (2002) 0.87
Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci (2008) 0.87
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry (2002) 0.87
Opioid addiction changes cerebral blood flow symmetry. Neuropsychobiology (2002) 0.87
Gray matter and intrinsic network changes in the posterior cingulate cortex after selective serotonin reuptake inhibitor intake. Neuroimage (2013) 0.87
A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol (2004) 0.87
A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl) (2003) 0.86
Effects of sunshine on suicide rates. Compr Psychiatry (2011) 0.86
Testosterone in the brain: neuroimaging findings and the potential role for neuropsychopharmacology. Eur Neuropsychopharmacol (2012) 0.86
Gender differences in the psychopathology of depressed inpatients. Eur Arch Psychiatry Clin Neurosci (2004) 0.86
The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int Clin Psychopharmacol (2010) 0.86
A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr (2013) 0.86
European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol (2012) 0.86
Serotonin-1A receptor binding is positively associated with gray matter volume -- a multimodal neuroimaging study combining PET and structural MRI. Neuroimage (2012) 0.86
Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol (2008) 0.85
Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and in healthy controls. Eur Neuropsychopharmacol (2004) 0.85
Sex-specific predictors of criminal recidivism in a representative sample of incarcerated youth. Compr Psychiatry (2008) 0.85
Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry (2011) 0.85
Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol (2009) 0.84
Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. Brain Struct Funct (2013) 0.84